Neurocrine Biosciences, Inc. presented subgroup analyses and data from the KINECT-HD study, showing the impact of INGREZZA capsules on emotional health and psychiatric stability in patients with chorea associated with Huntington's disease. The subgroup analysis demonstrated consistent efficacy in reducing chorea compared to placebo across all 19 identified subgroups.
A separate data analysis indicated improvements in some aspects of emotional health with no worsening of psychiatric symptoms, which is crucial given that Huntington's disease significantly affects emotional and psychological well-being. The least-squares mean (LSM) change for the Unified Huntington's Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) score showed significantly greater chorea improvements for INGREZZA versus placebo, with an LSM difference at maintenance of -3.2 (P < 0.0001).
These data support the consistent efficacy of INGREZZA in reducing chorea across various patient demographics and baseline assessment scores. The potential positive impact on emotional health due to reduced movements further highlights the comprehensive benefits of INGREZZA for patients with Huntington's disease.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.